Health, Science, and Politics
The Politics of Pharmacology and Public Health Implications: “Drug ad Spending Surged 460% from 1997 to 2016.”
My Perspectives on a Crossroads of Free Speech, Public Health, and Consumer Protection
Medication can be life-saving when used correctly, yet when misused, neglected, or uncontrolled, it can turn deadly. One powerful example I discussed before is the devastating effects of serotonin syndrome, a global issue with potentially fatal consequences if left unchecked
As a seasoned science and technology consultant, I have examined the impact of regulatory policies on public health. One area of interest is the politics of pharmacology, particularly the direct-to-consumer (DTC) advertising of prescription drugs — a practice permitted only in the United States and New Zealand yet banned nearly everywhere else.
Recently, I encountered discussions on my X Premium criticizing Robert F. Kennedy Jr.’s push to restrict drug advertising on American television, which some say could “take America backward.” However, understanding why the U.S. and New Zealand permit these ads and why other countries do not might shed light on an overlooked area of healthcare policy.
In Australia, where I live, direct-to-consumer (DTC) advertising of prescription medications is prohibited under the Therapeutic Goods Act 1989 and the Competition and Consumer Act 2010. This restriction aims to prevent potential public health risks associated with such advertising
I have been following this issue for a long time in scientific literature. The most informative and eye-opening one was a systematic review by Gilbody et al. (2005) in BMJ examining 2853 citations, which found that direct-to-consumer (DTC) pharmaceutical advertising, though heavily used, offers no demonstrated benefits for health outcomes.
The paper informed that DTC advertising drives increased prescriptions for advertised drugs, primarily influenced by patient requests, and affects physician prescribing confidence.
This review informed and supported concerns over the potential negative impact of DTC advertising, aligning with the rationale behind legislative bans in most countries. It also highlighted the need for further research on its clinical and economic effects.
After 2005, the scale of direct-to-consumer (DTC) pharmaceutical advertising grew significantly. A 2021 review published in Springer reported that spending on drug advertising rose from $17.7 billion in 1997 to $29.9 billion by 2016, with approximately 32% (~$10 billion) allocated to DTC advertising.
Although a larger portion of advertising funds still targets healthcare professionals, DTC spending surged by 460% from 1997 to 2016. This shift highlights that directly informing consumers about drug products, rather than solely relying on medical professionals, has become a strategic priority for pharmaceutical manufacturers.
While consumer outreach has historical precedents, the influence of modern media — such as television, radio, and digital platforms like social media — has expanded the reach of these advertisements to an unprecedented level. The differences in regulatory approaches have led to some international friction.
For example, when U.S. singer Lady Gaga promoted a migraine drug sponsored by Pfizer on Instagram, the ad became visible to her millions of followers, including those in the European Union — where DTC drug advertising is illegal.
This incident drew sharp criticism from European regulators, who viewed it as violating their strict advertising laws. Despite the singer’s disclaimer that the ad was “for U.S. audiences only,” its accessibility across borders highlighted the difficulty of enforcing advertising restrictions in a digital world.
The paper highlighted that these advertisements may result in inappropriate prescribing, create undue economic strain on an already overburdened healthcare system, and undermine the patient-physician relationship.
Moreover, a 2019 review in JAMA Network pointed out that despite the increase in marketing over the past twenty years, regulatory oversight remains limited.
Another study published in JAMA in 2023 asked the research question, “What drug characteristics are associated with larger proportions of promotional spending allocated to direct-to-consumer advertising?”
This study found that among the 150 top-selling U.S. prescription drugs in 2020, those with lower added clinical benefits spent a larger portion of their promotional budget on direct-to-consumer advertising than drugs with higher clinical benefits.
Additionally, drugs with higher sales are also devoted more to consumer ads. The findings suggest a pattern where drugs with less effectiveness focus heavily on consumer advertising, though further research is needed to assess the impact on treatment choices and healthcare costs.
Why the U.S. Allows Pharmaceutical Advertising: Empowerment or Overreach?
In the United States, the Food and Drug Administration (FDA) oversees DTC advertising. Advocates for pharmaceutical ads argue they empower consumers by informing them about treatment options and encouraging them to take an active role in managing their health.
For some, these ads provide essential information that might otherwise be difficult to access, helping patients ask better questions and engage in more informed discussions with healthcare providers.
However, I understand that the primary reason DTC pharmaceutical advertising is legally protected in the U.S. stems from a different aspect: commercial free speech.
Under the First Amendment, the U.S. Constitution grants protections for commercial speech, which courts have interpreted to include pharmaceutical advertising.
While this principle supports industry innovation and competition, it also makes banning such ads challenging without infringing on constitutional rights.
Yet, many health professionals argue that these ads create demand for expensive and often unnecessary medications, potentially putting public health at risk.
As the 2023 JAMA study highlighted, drugs with minimal therapeutic benefits often spend the most on consumer advertising, indicating that the influence of ads may skew treatment decisions toward less effective options.
Why New Zealand Follows a Similar Approach
After the US, New Zealand is the only other country allowing DTC pharmaceutical ads, albeit with a different regulatory philosophy.
Proponents argue that these ads enhance public awareness about health issues, providing a broader understanding of treatment options.
However, New Zealand’s regulatory framework mandates that advertisements be accurate and balanced, including clear communication of benefits and risks.
Even with these checks, DTC advertising in New Zealand raises concerns. Health experts worry that ads may lead patients to overestimate the effectiveness of certain treatments or to pressure healthcare providers for specific drugs based on marketing claims rather than medical advice.
Why the Rest of the World Prohibits Drug Ads on TV
DTC pharmaceutical advertising is strictly banned in countries across the European Union, Canada, and Australia.
The rationale behind this approach rests on several pillars: Public Health Risks, Preserving the Doctor-Patient Relationship, and Healthcare System Burden.
Regulatory bodies worry that DTC advertising could lead to overprescription, overdiagnosis, and reliance on medications without appropriate medical guidance.
In the European Union, for example, direct advertising to the public is seen as a potential risk that could fuel unnecessary medical spending and increase adverse health outcomes.
In many countries, healthcare professionals are considered the primary source of information about medications and treatment plans.
By banning DTC advertising, these countries aim to protect the integrity of clinical decision-making and allow medical guidance to be the primary driver of patient care.
Increased demand for advertised drugs can strain healthcare resources, driving up costs for already-pressured healthcare systems. Advertising can also lead to higher utilization of newer, often more expensive drugs that may not be more effective than alternatives.
The U.S. healthcare system, one of the world’s most expensive, demonstrates the high financial stakes of DTC advertising.
According to a Harvard University report, drug companies spend over $1 billion monthly on DTC ads, primarily targeting high-cost medications.
Research shows that over half of the drugs Medicare funds went toward heavily advertised medications, burdening public health budgets.
Critics argue that drug ads contribute to an emphasis on costly new drugs, sometimes with minor benefits over existing treatments.
Efforts to make DTC ads more transparent have faced challenges. In 2019, the Trump administration proposed requiring drug companies to disclose prices in ads for treatments over $35.
The industry, however, took legal action, arguing this requirement violated their First Amendment rights. Big Pharma ultimately won the case, illustrating the limits of regulatory efforts to make pharmaceutical advertising more transparent.
To address misleading claims, the FDA issued new guidance in 2023, asking that DTC ads present information “clearly, conspicuously, and neutrally.”
However, the guidelines lack specific definitions for terms like “neutral,” leaving room for pharmaceutical companies to interpret these rules creatively.
With limited enforcement capacity—just over 70 employees reviewing thousands of drug ads—the FDA relies on voluntary compliance from drugmakers and consumer complaints.
Conclusions and Takeaways
My understanding from the literature is that the unique regulatory environment in the U.S. and New Zealand reflects a balance of consumer autonomy and commercial free speech, but it also raises significant concerns in the healthcare industry.
While DTC pharmaceutical ads may promote awareness, they come with risks of overprescription, higher healthcare costs, and the erosion of trust in clinical decision-making.
As the only two countries permitting these ads, the U.S. and New Zealand face mounting pressure from health experts and policymakers to consider public health implications more closely.
Striking a better balance between free speech and consumer protection might involve stronger transparency requirements, a stricter review of ad content, and perhaps a reassessment of the role of advertising in healthcare.
I reflected on my findings and perspectives in this story and would appreciate your comments based on your observations in your countries.
Related to drugs, I wrote about my perspectives on alcohol, which is another big public health concern. I look forward to your comments on this issue as well if possible.
Are the World Health Organization and Cancer Institutes Wrong?
Some People Without Scientific Background Criticize Experts, Dismissing Ethanol’s Well-Documented, Consensus-Based…medium.com
Thank you for reading my perspectives. I wish you a healthy and happy life.
I am here to help my readers, so reach out when you need support. You may take a quick taste of some of my inspiring stories in this collection. If you wish, you may subscribe to my Health and Wellness newsletter to benefit from my decades of health, science, and technology experience.
If you are a new writer on this platform, you can join my publications by sending a request via this link. I support 33K writers who contribute to my publications on this platform. You can contact me via my website. I also have another profile to write and curate tech stories.
I also authored a recent book titled Substack Mastery to guide freelance writers to write insightful content and build their audiences.
You are welcome to join the ILLUMINATION Community on Medium and Substack and our education tool, Substack Mastery, curated by ILLUMINATION-Curators. Here is the Importance and Value of Medium Friendship for Writers and Readers.
You can join my newsletters, where I offer experience-based content on health, content strategy, and technology topics to inform and inspire my readers.
Get an email whenever Dr Mehmet Yildiz publishes. He is a top writer and editor on Medium.
Leave a Reply